Editas Medicine and Genevant Sciences announced a collaboration and nonexclusive license agreement on October 21, 2024. The partnership aims to combine Editas Medicine’s CRISPR Cas12a genome editing systems with Genevant’s proprietary lipid nanoparticle (LNP) technology.
This collaboration will focus on the development of in vivo gene editing medicines directed to two undisclosed targets within Editas Medicine's upregulation strategy. Genevant is eligible to receive up to $238 million in upfront and contingent milestone payments, in addition to tiered royalties on future product sales.
The agreement is expected to accelerate Editas Medicine's progress towards the clinic by leveraging Genevant's established leadership in LNP delivery. This strategic alliance is designed to complement Editas Medicine's gene editing technology for its in vivo upregulation approach.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.